CNCR — Loncar Cancer Immunotherapy ETF
Data updated: 2025-04-28
CNCR — Loncar Cancer Immunotherapy ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $8.93M AUM · 0.79% expense ratio · -33.3% 1-yr return. From SEC regulatory filings.
CNCR Fund Overview
CNCR — Loncar Cancer Immunotherapy ETF is a US ETF managed by ETF Series Solutions, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: ETF Series Solutions
- Category: United States Health Care Equity
- Assets under management: $8.93M
- 1-year return: -33.3%
- Ticker: CNCR
- SEC CIK: 0001540305
- SEC series ID: S000050740
- Share class ID: C000160229
CNCR Holdings
Top 10 holdings of Loncar Cancer Immunotherapy ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Recursion Pharmaceuticals Inc | 4.01% |
| Precigen Inc | 3.05% |
| Compass Therapeutics Inc | 2.99% |
| Genelux Corp | 2.90% |
| SpringWorks Therapeutics Inc | 2.86% |
| Exelixis Inc | 2.48% |
| Ginkgo Bioworks Holdings Inc | 2.33% |
| Replimune Group Inc | 2.14% |
| Bristol-Myers Squibb Co | 2.10% |
| Schrodinger Inc/United States | 1.98% |
CNCR Portfolio Allocation
Asset-class allocation of Loncar Cancer Immunotherapy ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.3% |
| Cash & Equivalents | 0.7% |
CNCR Performance
Total returns for CNCR (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| 1 year | -33.3% |
| 3 years (annualised) | -14.9% |
| 5 years (annualised) | -10.6% |
CNCR Risk Information
Risk metrics for CNCR, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 23.3%
CNCR Costs and Fees
CNCR costs about $79 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.79%
- Gross expense ratio: 0.79%
- Portfolio turnover: 52%
- Brokerage commissions: 19.64 bps of average net assets (SEC N-CEN)
CNCR Cashflows
Over the 12 months to 2025-02, Loncar Cancer Immunotherapy ETF had net outflows of $4.25M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2025-02 | $0 |
| 2025-01 | −$610.03K |
| 2024-12 | $0 |
| 2024-11 | $0 |
| 2024-10 | −$2.25M |
| 2024-09 | $1.47M |
CNCR Debt Constituents
No individual debt constituents are reported in Loncar Cancer Immunotherapy ETF's latest SEC N-PORT filing.
CNCR Prospectus and SEC Filings
Official Loncar Cancer Immunotherapy ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.